<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Liq</journal-id><journal-id journal-id-type="iso-abbrev">J Mol Liq</journal-id><journal-title-group><journal-title>Journal of Molecular Liquids</journal-title></journal-title-group><issn pub-type="ppub">0167-7322</issn><issn pub-type="epub">1873-3166</issn><publisher><publisher-name>Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7399655</article-id><article-id pub-id-type="publisher-id">S0167-7322(20)33193-7</article-id><article-id pub-id-type="doi">10.1016/j.molliq.2020.113968</article-id><article-id pub-id-type="publisher-id">113968</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name><surname>El-hoshoudy</surname><given-names>A.N.</given-names></name><email>azizchemist@yahoo.com</email></contrib><aff id="af0005">Computational Chemistry Group, Egyptian Petroleum Research Institute, 11727 Nasr City, Cairo, Egypt</aff></contrib-group><pub-date pub-type="pmc-release"><day>4</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>15</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>4</day><month>8</month><year>2020</year></pub-date><volume>318</volume><fpage>113968</fpage><lpage>113968</lpage><history><date date-type="received"><day>19</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>19</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab0005"><p>Recently, scary viral pneumonia is known as (COVID-19) has swept the whole world. The new virus strain designated as SARS-CoV-2 belonging to the coronavirus family. Although the current medical research directed towards the development of a novel therapeutic agent, no anti-viral drug approved until now. On the medical scale, the development of an approved drug is a time-consuming process, so research is directed towards screening of ligands and drugs multimodal structure-based-design and then docked to the main viral protease to investigate the active binding sites. The bioinformatic approaches used to evaluate the competence of a comprehensive range of ligands and drugs before their clinical implementation. In this study, a computational approach through molecular docking simulation is conducted for screening the antiviral activity of drugs, natural sources, and inhibitory compounds against the SARS-CoV-2 genome. The main virus protease was collected from a Protein Data Bank (PDB# <ext-link ext-link-type="uri" xlink:href="pdb:6YB7" id="ir0005">6YB7</ext-link>) and docked with a sequence of 19 approved antiviral drugs, 10 natural inhibitory ligands against COVID-19 downloaded from PubChem, in addition to 10 natural sources optimized for <italic>Escherichia coli</italic> BL<sub>21</sub> (DE<sub>3</sub>) to identify the antiviral activity of these candidates against COVID-19. The docking results were promised and indicated that the reported ligands can firmly bind to the SARS-CoV-2 main protease and leads to inhibition of its infectious impact.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>&#x02022;</label><p id="p0005">SARS-CoV-2 main protease</p></list-item><list-item id="li0010"><label>&#x02022;</label><p id="p0010">Screening of antiviral effectivity by molecular docking</p></list-item><list-item id="li0015"><label>&#x02022;</label><p id="p0015">Ritonavir is a potent inhibitor for SARS-CoV-2 pneumonia.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Coronavirus</kwd><kwd>Molecular docking</kwd><kwd>SARS-CoV-2</kwd><kwd>Homology modeling</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0020">The recent world history is punctuated by the appearance of highly pathogenic three coronaviruses which cause human fatal pneumonia including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0010" ref-type="bibr">2</xref>]. The SARS-CoV epidemic in 2002 and the MERS-CoV epidemic in 2012 proved that coronaviruses would traverse the barrier to species and develop as severe pathogenic viruses [<xref rid="bb0015" ref-type="bibr">3</xref>]. Coronaviruses (CoVs), are divided into four genera, &#x003b1;-, &#x003b2;-, &#x003b4;- and &#x003b3;-coronaviruses [<xref rid="bb0020" ref-type="bibr">4</xref>]. SARS-CoV-2 is a member of &#x003b2;-coronaviruses which subdivided into A, B, C, and D lineages [<xref rid="bb0025" ref-type="bibr">5</xref>]. Robson [<xref rid="bb0030" ref-type="bibr">6</xref>] defined SARS-CoV-2 viral protein as a strain of human SARS [<xref rid="bb0035" ref-type="bibr">7</xref>]. SARS-CoV-2 which synonymously known as (COVID-19) virus was commenced in the late of December 2019 [<xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0040" ref-type="bibr">[8]</xref>, <xref rid="bb0045" ref-type="bibr">[9]</xref>] as an outbreak of pneumonia with a mysterious etiological agent responsible for the viral pneumonia outbreak that swept the world [<xref rid="bb0020" ref-type="bibr">4</xref>,<xref rid="bb0040" ref-type="bibr">8</xref>,<xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0060" ref-type="bibr">[12]</xref>, <xref rid="bb0065" ref-type="bibr">[13]</xref>, <xref rid="bb0070" ref-type="bibr">[14]</xref>, <xref rid="bb0075" ref-type="bibr">[15]</xref>, <xref rid="bb0080" ref-type="bibr">[16]</xref>, <xref rid="bb0085" ref-type="bibr">[17]</xref>, <xref rid="bb0090" ref-type="bibr">[18]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>], and created a significant threat to the global community health [<xref rid="bb0020" ref-type="bibr">4</xref>]. On 30th, January 2020 the World Health Organization (WHO) announced that COVID-19 epidemic a global health crisis of international interest [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0100" ref-type="bibr">20</xref>,<xref rid="bb0105" ref-type="bibr">21</xref>]. On 14th, March 2020, the disease infect 81,026 people in China, with a case fatality ratio of 3.9% (3194/81026) [<xref rid="bb0110" ref-type="bibr">22</xref>]. The number of victims increases incrementally and can be monitored by the WHO statistics website (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019" id="ir0010">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>). Respiratory globules and direct communication are traditional transmission routes for SARS-CoV-2 [<xref rid="bb0115" ref-type="bibr">23</xref>]. Common infection symptoms include respiratory distress, malaise, fever, dry cough, dyspnea, and shortness of breath [<xref rid="bb0040" ref-type="bibr">8</xref>,<xref rid="bb0070" ref-type="bibr">14</xref>]. In advanced serious cases, the infection can cause pneumonia, kidney failure, severe acute respiratory disorder, and even death [<xref rid="bb0005" ref-type="bibr">1</xref>]. The remedies of coronavirus infection involve inhibition of the synthesis of viral RNA through prohibiting the virus's genetic material, inhibiting virus replication, and blocking the virus binding to human cell receptors or inhibiting the virus's self-assembly process through acting on some structural proteins [<xref rid="bb0005" ref-type="bibr">1</xref>]. Coronaviruses (CoVs) comprise two characteristic proteins; 1) structural proteins which include Spike (S), Nucleocapsid (N), Membrane (M) that spans the membrane, and Envelope (E) proteins which are a hydrophobic protein that covers the entire structure of the coronavirus [<xref rid="bb0120" ref-type="bibr">24</xref>]; and 2) non-structural proteins which include proteases (nsp3 and nsp5) and RdRp (nsp12) [<xref rid="bb0070" ref-type="bibr">14</xref>,<xref rid="bb0125" ref-type="bibr">25</xref>]. The transmembrane spike (S) glycoprotein forms homotrimers projecting from the virion envelope surface [<xref rid="bb0130" ref-type="bibr">26</xref>] and promotes viral entry into the host cell [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0135" ref-type="bibr">27</xref>] in addition to facilitating the binding of the host and viral tissues [<xref rid="bb0140" ref-type="bibr">28</xref>]. The S protein is a single-chain comprises of about 1300 amino acids [<xref rid="bb0035" ref-type="bibr">7</xref>] and subdivided into two functional subunits (S1 and S2). The S1 subunit has a receptor-binding domain (RBD) that binds with high affinity to host cell receptor (angiotensin-converting enzyme 2; ACE-2 protein) which considered the key determinant of virus contagiousness [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0145" ref-type="bibr">[29]</xref>, <xref rid="bb0150" ref-type="bibr">[30]</xref>, <xref rid="bb0155" ref-type="bibr">[31]</xref>]. After fusion, the S2 subunit has the N-terminal domain (NTD) [<xref rid="bb0155" ref-type="bibr">31</xref>] responsible for binding between the virus and cellular host cell membrane [<xref rid="bb0160" ref-type="bibr">32</xref>]. The virus entry into the host cell requires the cleavage of S1-S2 subunits at the boundary to reveal S2 for combination to the cell membrane [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>,<xref rid="bb0165" ref-type="bibr">33</xref>]. For all coronaviruses, the S protein is further cleaved by host proteases [<xref rid="bb0170" ref-type="bibr">34</xref>]. S trimers are densely decorated by heterogeneous N-linked glycans protruding from the trimer surface and important for proper folding and modulating availability to host proteases and neutralizing antibodies [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0175" ref-type="bibr">35</xref>,<xref rid="bb0180" ref-type="bibr">36</xref>]. SARS-CoV-2 is an enveloped, positive single RNA strand coronavirus with a genome sequence ranging from 26.0 to 32.0 kilobases [<xref rid="bb0185" ref-type="bibr">[37]</xref>, <xref rid="bb0190" ref-type="bibr">[38]</xref>, <xref rid="bb0195" ref-type="bibr">[39]</xref>]. On 10th January 2020, the viral genome was released on NCBI GenBank. The first high-resolution crystal structure of SARS-CoV-2 main protease released on February 5th, 2020 on Protein Data Bank (PDB) Doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb6lu7/pdb" id="ir0015">https://doi.org/10.2210/pdb6lu7/pdb</ext-link> [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0035" ref-type="bibr">7</xref>]. 6LU7 is the monomer of the main protease in the active state with the N3 peptidomimetic inhibitor [<xref rid="bb0200" ref-type="bibr">40</xref>]. On 25th March 2020, 6YB7 released as SARS-CoV-2 main protease with unliganded active site (2019-nCoV, coronavirus disease 2019, COVID-19) DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb6YB7/pdb" id="ir0020">https://doi.org/10.2210/pdb6YB7/pdb</ext-link>. Although the current medical research proceeds urgently to diagnose active antiviral agents that can inhibit the pandemic spread of the novel viral infection, no targeted/approved therapeutic drug or vaccine has been accredited till now as it is a time-consuming process [<xref rid="bb0005" ref-type="bibr">1</xref>,<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0155" ref-type="bibr">31</xref>,<xref rid="bb0205" ref-type="bibr">41</xref>]. Consequently, the swift approach relies on the use of computational programs of combined structure-assisted drug design, bioinformatics, and drug screening [<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0210" ref-type="bibr">42</xref>], in addition to the development of a predictive 3D protein structures of SARS-CoV-2 has become very crucial to identify new inhibitory drugs for SARS-CoV-2 protease [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0215" ref-type="bibr">43</xref>]. Roboson [<xref rid="bb0035" ref-type="bibr">7</xref>] stated the usage of the Q-UEL computational method to simulate the inhibition efficiency of some drugs on COVID-19. In this work, the author conducting a computational approach, through applying a combination of virtual screening, and molecular docking techniques, to assess the ability of some potential drugs, inhibitory ligands and natural products for the non-covalent inhibition of the SARS-CoV-2 main protease [<xref rid="bb0200" ref-type="bibr">40</xref>] through conformational and molecular docking studies. Molecular docking allows quick identification of the amino acid sequences across many coronaviruses including SARS-CoV-2 [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0220" ref-type="bibr">44</xref>]. The obtained docking results were hopeful and proposed a potential inhibition against the newly emerged COVID-19 from the presently accessible therapeutics [<xref rid="bb0005" ref-type="bibr">1</xref>].</p></sec><sec id="s0010"><label>2</label><title>Materials and reagents</title><p id="p0025">All the screened drugs, inhibitory ligands, and natural product structures were built up from their smile format in ChemBioDraw 2019 software. All the molecules were energy minimized before molecular docking simulation [<xref rid="bb0155" ref-type="bibr">31</xref>]. The screened compounds comprise three categories divided as follows; 19 approved antiviral drugs presently available on the market and have been authorized for use against a variety of viruses. 10 natural inhibitors ligands against COVID-19 were downloaded from PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/#query=coronavirus&#x00026;tab=compound&#x00026;page=4" id="ir0025">https://pubchem.ncbi.nlm.nih.gov/#query=coronavirus&#x00026;tab=compound&#x00026;page=4</ext-link>) and selected according to H-bond donor count, and 10 natural compounds selected from the natural sources site available at <ext-link ext-link-type="uri" xlink:href="http://bioinf-applied.charite.de/supernatural_new/index.php?site=pathway&#x00026;organism=ebe&#x00026;pathway_type=Genetic%20Information%20Processing" id="ir0030">http://bioinf-applied.charite.de/supernatural_new/index.php?site=pathway&#x00026;organism=ebe&#x00026;pathway_type=Genetic%20Information%20Processing</ext-link>. The full-length gene encoding COVID-19 virus was optimized for <italic>Escherichia coli</italic> BL21 (DE3) expression [<xref rid="bb0050" ref-type="bibr">10</xref>]. <xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>
summarize the structure of the compounds for the three categories respectively.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Summary of the approved antiviral drugs.</p></caption><alt-text id="al0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Cpd.</th><th>Structure/IUPAC name</th><th>Biological activity</th></tr></thead><tbody><tr><td>1</td><td>Emodin</td><td><inline-graphic xlink:href="t1_lrg.gif"><alt-text id="al0020">Image 1</alt-text></inline-graphic></td><td>Inhibitor of SARS-CoV entry [<xref rid="bb0035" ref-type="bibr">7</xref>]</td></tr><tr><td>2</td><td>Chloroquine</td><td><inline-graphic xlink:href="t2_lrg.gif"><alt-text id="al0025">Image 2</alt-text></inline-graphic></td><td>Treatment of SARS-CoV-2 [<xref rid="bb0225" ref-type="bibr">45</xref>]</td></tr><tr><td>3</td><td>hydroxychloroquine</td><td><inline-graphic xlink:href="t3_lrg.gif"><alt-text id="al0030">Image 3</alt-text></inline-graphic></td><td>Treatment of SARS-CoV-2 [<xref rid="bb0225" ref-type="bibr">45</xref>]</td></tr><tr><td>4</td><td>Remdesivir</td><td><inline-graphic xlink:href="t4_lrg.gif"><alt-text id="al0035">Image 4</alt-text></inline-graphic></td><td>Antiviral drug [<xref rid="bb0230" ref-type="bibr">46</xref>]</td></tr><tr><td>5</td><td>Aminoquinoline</td><td><inline-graphic xlink:href="t5_lrg.gif"><alt-text id="al0040">Image 5</alt-text></inline-graphic></td><td>Used in malaria treatment [<xref rid="bb0045" ref-type="bibr">9</xref>]</td></tr><tr><td>6</td><td>Azithromycin</td><td><inline-graphic xlink:href="t6_lrg.gif"><alt-text id="al0045">Image 6</alt-text></inline-graphic></td><td>Broad spectrum antibiotic [<xref rid="bb0060" ref-type="bibr">12</xref>]</td></tr><tr><td>7</td><td>ethyl (3<italic>S</italic>)-1-(2a,8a-di(furan-2-yl)-2-oxo-1,2,2a,8a-tetrahydroazeto[2,3-<italic>b</italic>]quinoxalin-6-yl)piperidine-3-carboxylate</td><td><inline-graphic xlink:href="t7_lrg.gif"><alt-text id="al0050">Image 7</alt-text></inline-graphic></td><td rowspan="3">Cyclophilin D (CypD) inhibitors [<xref rid="bb0235" ref-type="bibr">47</xref>]</td></tr><tr><td>8</td><td>2,3-di(furan-2-yl)-6-ethoxycarbonylamino quinoxaline</td><td><inline-graphic xlink:href="t8_lrg.gif"><alt-text id="al0055">Image 8</alt-text></inline-graphic></td></tr><tr><td>9</td><td>2,3-di(furan-2-yl)-6-((<italic>R</italic>)-3-ethoxycarbonyl-piperidino) carbonylamino quinoxaline</td><td><inline-graphic xlink:href="t9_lrg.gif"><alt-text id="al0060">Image 9</alt-text></inline-graphic></td></tr><tr><td>10</td><td>Cyclosporine A</td><td><inline-graphic xlink:href="t10_lrg.gif"><alt-text id="al0065">Image 10</alt-text></inline-graphic></td><td>In vitro effective against HIV, HCV and HBV replication [<xref rid="bb0240" ref-type="bibr">48</xref>,<xref rid="bb0245" ref-type="bibr">49</xref>]</td></tr><tr><td/><td align="char"/><td/><td align="char"/></tr><tr><td>11</td><td>Lopinavir</td><td><inline-graphic xlink:href="t11_lrg.gif"><alt-text id="al0070">Image 11</alt-text></inline-graphic></td><td>(HIV protease inhibitors) [<xref rid="bb0020" ref-type="bibr">4</xref>]</td></tr><tr><td>12</td><td>Ritonavir</td><td><inline-graphic xlink:href="t12_lrg.gif"><alt-text id="al0075">Image 12</alt-text></inline-graphic></td><td/></tr><tr><td/><td align="char"/><td/><td align="char"/></tr><tr><td>13</td><td>Favipiravir</td><td><inline-graphic xlink:href="t13_lrg.gif"><alt-text id="al0080">Image 13</alt-text></inline-graphic></td><td>SARS-CoV-2 antiviral agent [<xref rid="bb0020" ref-type="bibr">4</xref>]</td></tr><tr><td/><td align="char"/><td/><td align="char"/></tr><tr><td>14</td><td>Ribavirin</td><td><inline-graphic xlink:href="t14_lrg.gif"><alt-text id="al0085">Image 14</alt-text></inline-graphic></td><td>HCV antiviral [<xref rid="bb0185" ref-type="bibr">37</xref>]</td></tr><tr><td>15</td><td>Tideglusib</td><td><inline-graphic xlink:href="t15_lrg.gif"><alt-text id="al0090">Image 15</alt-text></inline-graphic></td><td>Antiviral agent [<xref rid="bb0050" ref-type="bibr">10</xref>]</td></tr><tr><td/><td align="char"/><td/><td align="char"/></tr><tr><td>16</td><td>Disulfiram</td><td><inline-graphic xlink:href="t16_lrg.gif"><alt-text id="al0095">Image 16</alt-text></inline-graphic></td><td rowspan="2">FDA-approved drugs [<xref rid="bb0050" ref-type="bibr">10</xref>]</td></tr><tr><td>17</td><td>Carmofur</td><td><inline-graphic xlink:href="t17_lrg.gif"><alt-text id="al0100">Image 17</alt-text></inline-graphic></td></tr><tr><td>18</td><td>Ebselen</td><td><inline-graphic xlink:href="t18_lrg.gif"><alt-text id="al0105">Image 18</alt-text></inline-graphic></td><td>Currently in clinical trials [<xref rid="bb0050" ref-type="bibr">10</xref>]</td></tr><tr><td>19</td><td>Cinanserin</td><td><inline-graphic xlink:href="t19_lrg.gif"><alt-text id="al0110">Image 19</alt-text></inline-graphic></td><td>Antiviral drug [<xref rid="bb0050" ref-type="bibr">10</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Summary of the natural sources optimized for <italic>Escherichia coli</italic> BL<sub>21</sub> (DE<sub>3</sub>).</p></caption><alt-text id="al0115">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Natural Cpd. name</th><th>Serial No.</th><th>Structure/IUPAC name</th></tr></thead><tbody><tr><td>1</td><td>L-tyrosine zwitterion</td><td>SN0000130</td><td><inline-graphic xlink:href="t20_lrg.gif"><alt-text id="al0120">Image 20</alt-text></inline-graphic></td></tr><tr><td>2</td><td>L-threonine zwitterion</td><td>SN00001733</td><td><inline-graphic xlink:href="t21_lrg.gif"><alt-text id="al0125">Image 21</alt-text></inline-graphic></td></tr><tr><td>3</td><td>(2<italic>S</italic>,4<italic>R</italic>)-2-ammonio-4-carbamoylpentanedioate</td><td>SN00160264</td><td><inline-graphic xlink:href="t22_lrg.gif"><alt-text id="al0130">Image 22</alt-text></inline-graphic></td></tr><tr><td>4</td><td>L-leucine</td><td>SN00003439</td><td><inline-graphic xlink:href="t23_lrg.gif"><alt-text id="al0135">Image 23</alt-text></inline-graphic></td></tr><tr><td>5</td><td>L-alanine zwitterion</td><td>SN00011326</td><td><inline-graphic xlink:href="t24_lrg.gif"><alt-text id="al0140">Image 24</alt-text></inline-graphic></td></tr><tr><td>6</td><td>(2<italic>R</italic>)-2-ammonio-4-(ethylsulfanyl)butanoate</td><td>SN00002388</td><td><inline-graphic xlink:href="t25_lrg.gif"><alt-text id="al0145">Image 25</alt-text></inline-graphic></td></tr><tr><td>7</td><td>(4-(((2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl)methyl)amino)benzoyl)glutamic acid</td><td>SN00193091</td><td><inline-graphic xlink:href="t26_lrg.gif"><alt-text id="al0150">Image 26</alt-text></inline-graphic></td></tr><tr><td>8</td><td>(2<italic>S</italic>)-2-ammonio-3-(3-methylimidazol-4-yl)propanoate</td><td>SN00001765</td><td><inline-graphic xlink:href="t27_lrg.gif"><alt-text id="al0155">Image 27</alt-text></inline-graphic></td></tr><tr><td>9</td><td>D-asparagine</td><td>SN00156119</td><td><inline-graphic xlink:href="t28_lrg.gif"><alt-text id="al0160">Image 28</alt-text></inline-graphic></td></tr><tr><td>10</td><td>O-phosphonato-<sc>l</sc>-serine(2-)</td><td>SN00005709</td><td><inline-graphic xlink:href="t29_lrg.gif"><alt-text id="al0165">Image 29</alt-text></inline-graphic></td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Summary of inhibitory ligands against COVID-19 downloaded from the PubChem.</p></caption><alt-text id="al0170">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Compound CID</th><th>Structure/IUPAC name</th></tr></thead><tbody><tr><td>1</td><td align="char">24758425</td><td><inline-graphic xlink:href="t30_lrg.gif"><alt-text id="al0175">Image 30</alt-text></inline-graphic></td></tr><tr><td>2</td><td align="char">445794</td><td><inline-graphic xlink:href="t31_lrg.gif"><alt-text id="al0180">Image 31</alt-text></inline-graphic></td></tr><tr><td>3</td><td align="char">6083</td><td><inline-graphic xlink:href="t32_lrg.gif"><alt-text id="al0185">Image 32</alt-text></inline-graphic></td></tr><tr><td>4</td><td align="char">24139</td><td><inline-graphic xlink:href="t33_lrg.gif"><alt-text id="al0190">Image 33</alt-text></inline-graphic></td></tr><tr><td>5</td><td align="char">24310</td><td><inline-graphic xlink:href="t34_lrg.gif"><alt-text id="al0195">Image 34</alt-text></inline-graphic></td></tr><tr><td>6</td><td align="char">439680</td><td><inline-graphic xlink:href="t35_lrg.gif"><alt-text id="al0200">Image 35</alt-text></inline-graphic></td></tr><tr><td>7</td><td align="char">311</td><td><inline-graphic xlink:href="t36_lrg.gif"><alt-text id="al0205">Image 36</alt-text></inline-graphic></td></tr><tr><td>8</td><td align="char">787400</td><td><inline-graphic xlink:href="t37_lrg.gif"><alt-text id="al0210">Image 37</alt-text></inline-graphic></td></tr><tr><td>9</td><td align="char">753</td><td><inline-graphic xlink:href="t38_lrg.gif"><alt-text id="al0215">Image 38</alt-text></inline-graphic></td></tr><tr><td>10</td><td align="char">17754054</td><td><inline-graphic xlink:href="t39_lrg.gif"><alt-text id="al0220">Image 39</alt-text></inline-graphic></td></tr></tbody></table></table-wrap></p><sec id="s0015"><label>2.1</label><title>Sequence alignment and homology modeling</title><p id="p0030">The recently emerged SARS-CoV-2 nucleotide gene was retrieved from the protein data bank (PDB ID: <ext-link ext-link-type="uri" xlink:href="pdb:6YB7" id="ir0035">6YB7</ext-link>, chain A) since it is the last approved SARS-CoV-2 main protease during the editing of this manuscript. 6YB7 is the monomer of the main protease with the unliganded active site [<xref rid="bb0200" ref-type="bibr">40</xref>]. The sequence was downloaded as a PDB format. 6YB7 is SARS-CoV-2 main protease with 306 sequence length and 1.25&#x000a0;&#x000c5; resolution. The protein sequence stated in <xref rid="t0020" ref-type="table">Table 4</xref>
, while the crystal 3D structure of COVID-19 main protease shown in <xref rid="f0005" ref-type="fig">Fig. 1</xref>
. The model validated after the addition of missed hydrogen atoms to prepare the protonated 3D-structure for the docking study [<xref rid="bb0070" ref-type="bibr">14</xref>]. After validation, the systems were energy-minimized [<xref rid="bb0250" ref-type="bibr">50</xref>] to obtain a fully optimized and stable structure for further docking simulation. Energy minimization carried out using Amber10: EHT forcefield with current forcefield charges applied to all atoms, R-field solvation, cutoff (8,10&#x000a0;&#x000c5;), and distance-dependent dielectric constant of 4.0 [<xref rid="bb0235" ref-type="bibr">47</xref>]. Amber parameters applied for nucleic acid, and EHT parameters applied for small molecules. The system conducted in a triclinic non-periodic cell (1.P1) with a size of 10&#x000a0;&#x000d7;&#x000a0;10&#x000a0;&#x000d7;&#x000a0;10 and cell shape 90&#x000a0;&#x000d7;&#x000a0;90&#x000a0;&#x000d7;&#x000a0;90. The constraints including rigid water molecules with a gradient of 0.1 RMS kcal/mol/A<sup>2</sup>. Docked complexes were subsequently submitted to iterative cycles of 500 maximum iterations with a gradient of 0.01, radius offset of 0.4, and one minimization cycle [<xref rid="bb0235" ref-type="bibr">47</xref>].<table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>Sequence structure of SARS-CoV-2 main protease.</p></caption><alt-text id="al0225">Table 4</alt-text><table frame="hsides" rules="groups"><tbody><tr><td><bold>QUERY</bold>: Sequence&#x000a0;=&#x000a0;SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNHNFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCAMRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQAAGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGIAVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ<break/><bold>AND</bold> Target&#x000a0;=&#x000a0;Protein <bold>AND</bold> E-Value Cutoff&#x000a0;=&#x000a0;1,000,000 <bold>AND</bold> Identity Cutoff&#x000a0;=&#x000a0;0</td></tr></tbody></table></table-wrap><fig id="f0005"><label>Fig. 1</label><caption><p>(a) Cladogram representation of SARS-CoV-2 main protease; (b) 6YB7-SARS-CoV-2 main protease with unliganded active site (c) crystal 3D structure of 6YB7- main protease.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="s0020"><label>2.2</label><title>Molecular docking simulation</title><p id="p0035">In this study, the SARS-CoV-2 main protease was retrieved from the protein data bank (PDB ID: <ext-link ext-link-type="uri" xlink:href="pdb:6YB7" id="ir0040">6YB7</ext-link>, chain A) [<xref rid="bb0070" ref-type="bibr">14</xref>]. After model validation, alignment of the protein sequences, and subsequent molecular docking conducted to evaluate the antiviral effect of the previously reported drugs, and natural sources against SARS-CoV-2 protease. The binding energies and the inhibition constants are reported in each case [<xref rid="bb0220" ref-type="bibr">44</xref>]. All of the compounds were optimized in their active physiological settings [<xref rid="bb0255" ref-type="bibr">51</xref>]. Before testing the ligands against SARS-CoV-2 protease, the structures of the tested drugs and ligands were ensured to be in the optimized active arrangement. Finally, the ligands selected based on analyzing the predicted binding modes and their scores [<xref rid="bb0050" ref-type="bibr">10</xref>].</p></sec></sec><sec id="s0025"><label>3</label><title>Results and discussion</title><p id="p0040">Compounds with lower molecular docking scores will have higher binding correspondences with the target 6YB7 protein [<xref rid="bb0005" ref-type="bibr">1</xref>]. The orientation of a ligand is evaluated with a shape-scoring function which approximates the binding energies of the ligand-receptor. The shape-scoring function is an empirical function resembling the van der Waals' attractive energy. After the initial orientation and scoring evaluation, energy minimization is conducted to pinpoint the closest energy minimization points within the receptor-binding sites [<xref rid="bb0235" ref-type="bibr">47</xref>]. Most of the tested ligands (39 ligands) including the 19 antiviral drugs, 10 natural inhibitory ligands, and 10 natural sources optimized for <italic>Escherichia coli</italic> bear hydrogen bond acceptors or donors [<xref rid="bb0200" ref-type="bibr">40</xref>] and exhibit excessive H-bonding, <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction and/or hydrophobic interaction with the 6YB7 protease as summarized in <xref rid="t0025" ref-type="table">Table 5</xref>, <xref rid="t0030" ref-type="table">Table 6</xref>, <xref rid="t0035" ref-type="table">Table 7</xref>
. These electrostatic interactions imply that these ligands are potent inhibitors for the SARS-CoV-2 protease [<xref rid="bb0005" ref-type="bibr">1</xref>], since, the formed complex between the screened ligands and SARS-CoV-2 main protease is highly stable with higher binding energies. The formation of excessive hydrogen bonding with the main protease chain indicates the ability of the ligand to lock the virus-binding receptor [<xref rid="bb0050" ref-type="bibr">10</xref>]. By analyzing the docking results, it's found that <bold>Ritonavir</bold> antiviral drug, [[(2<italic>R</italic>,3<italic>S</italic>,4<italic>R</italic>,5<italic>R</italic>)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxyhydroxyphosphoryl] [(2<italic>R</italic>,3<italic>S</italic>,4<italic>R</italic>,5<italic>R</italic>)-3,4,5-trihydroxyoxolan-2-yl]methyl hydrogen phosphate (<bold>Cpd</bold>. <bold>CID</bold> (<bold>445794</bold>)), and (4-(((2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl)methyl)amino)benzoyl)glutamic acid (<bold>Cpd</bold>. <bold>Serial No</bold>.# <bold>SN00193091</bold>) exhibits the highest binding affinity, in case of the antiviral drugs, inhibitory ligands, and natural sources optimized for <italic>Escherichia coli</italic> with binding energies of &#x02212;8.12, &#x02212;6.39, &#x02212;7.17, kcal/mol, respectively. The docking results indicate that these ligands can bind tightly to the new COVID-19 protease and disorder the polymerase function. Consequently, these ligands are potent inhibiting candidates for 6YB7 main protease of the SARS-CoV-2. <xref rid="f0010" ref-type="fig">Fig. 2</xref>a&#x02013;c illustrates the highest thee ligands interaction with their surface maps successively, while other ligands-6YB7 protease interactions are provided in supplementary data (Tables S1&#x02013;S3). Based on the binding energies and docking scores, <bold>Ritonavir</bold> antiviral drug considered as the strongest inhibiting agent rather than other screened 39 ligands with a higher binding energy of &#x02212;8.12&#x000a0;kcal/mol. Furthermore, <bold>Ritonavir</bold> found to have a strong binding pattern with aromatic moieties, so it is the most potent docked ligands [<xref rid="bb0200" ref-type="bibr">40</xref>]. The docking study exhibited that the screened ligands inhibit coronaviruses and illuminate the road for medical scientists to develop in-vivo and in-vitro compounds against COVID-19.<table-wrap position="float" id="t0025"><label>Table 5</label><caption><p>Summary of docking interactions in case of the antiviral drugs.</p></caption><alt-text id="al0230">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Cpd. name</th><th>Docking interaction</th><th>Docking score</th><th>Interpretation</th></tr></thead><tbody><tr><td>1</td><td>Emodin</td><td><inline-graphic xlink:href="t40_lrg.gif"><alt-text id="al0235">Image 40</alt-text></inline-graphic></td><td align="char">&#x02212;5.37</td><td>H-bond with Met165, <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> bonding with Gly143</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>2</td><td>Chloroquine</td><td><inline-graphic xlink:href="t41_lrg.gif"><alt-text id="al0240">Image 41</alt-text></inline-graphic></td><td align="char">&#x02212;5.95</td><td/></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>3</td><td>Remdesivir</td><td><inline-graphic xlink:href="t42_lrg.gif"><alt-text id="al0245">Image 42</alt-text></inline-graphic></td><td align="char">&#x02212;7.12</td><td>2-H bonding with Arg40, arene cation bonding between Arg188 and pyrrole ring</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>4</td><td>Aminoquinoline</td><td><inline-graphic xlink:href="t43_lrg.gif"><alt-text id="al0250">Image 43</alt-text></inline-graphic></td><td align="char">&#x02212;5.21</td><td/></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>5</td><td>Ethyl (3<italic>S</italic>)-1-(2a,8a-di(furan-2-yl)-2-oxo-1,2,2a,8a-tetrahydroazeto[2,3-<italic>b</italic>]quinoxalin-6-yl)piperidine-3-carboxylate</td><td><inline-graphic xlink:href="t44_lrg.gif"><alt-text id="al0255">Image 44</alt-text></inline-graphic></td><td align="char">&#x02212;6.30</td><td/></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>6</td><td>2,3-di(furan-2-yl)-6-ethoxycarbonylamino quinoxaline</td><td><inline-graphic xlink:href="t45_lrg.gif"><alt-text id="al0260">Image 45</alt-text></inline-graphic></td><td align="char">&#x02212;5.99</td><td>H-bonding with Met17, arene-h-bonding between Glu14 and pyridazine ring, arene-H-bonding between Lys97 and furan ring</td></tr><tr><td>7</td><td>Azithromycin</td><td><inline-graphic xlink:href="t46_lrg.gif"><alt-text id="al0265">Image 46</alt-text></inline-graphic></td><td align="char">&#x02212;6.58</td><td>3-H-bonding with lys137 and Glu290</td></tr><tr><td>8</td><td>Ethyl (3<italic>S</italic>)-1-(2a,8a-di(furan-2-yl)-2-oxo-1,2,2a,8a-tetrahydroazeto [2,3-b]quinoxalin-6-yl) piperidine-3-carboxylate</td><td><inline-graphic xlink:href="t47_lrg.gif"><alt-text id="al0270">Image 47</alt-text></inline-graphic></td><td align="char">&#x02212;6.61</td><td>Arene-H-bonding with Arg76, Asp92</td></tr><tr><td>9</td><td>Cyclosporine A</td><td><inline-graphic xlink:href="t48_lrg.gif"><alt-text id="al0275">Image 48</alt-text></inline-graphic></td><td align="char">&#x02212;7.81</td><td>Excessive <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Asn218, Asp197, Thr199, and Arg131</td></tr><tr><td>10</td><td>Lopinavir</td><td><inline-graphic xlink:href="t49_lrg.gif"><alt-text id="al0280">Image 49</alt-text></inline-graphic></td><td align="char">&#x02212;7.57</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Lys137</td></tr><tr><td>11</td><td>Ritonavir</td><td><inline-graphic xlink:href="t50_lrg.gif"><alt-text id="al0285">Image 50</alt-text></inline-graphic></td><td align="char">&#x02212;8.12</td><td>Arene-H-bonding with Met165</td></tr><tr><td>12</td><td>Favipiravir</td><td><inline-graphic xlink:href="t51_lrg.gif"><alt-text id="al0290">Image 51</alt-text></inline-graphic></td><td align="char">&#x02212;4.95</td><td>H-bonding with Ala7</td></tr><tr><td>13</td><td>Ribavirin</td><td><inline-graphic xlink:href="t52_lrg.gif"><alt-text id="al0295">Image 52</alt-text></inline-graphic></td><td align="char">&#x02212;5.05</td><td/></tr><tr><td>14</td><td>Disulfiram</td><td><inline-graphic xlink:href="t53_lrg.gif"><alt-text id="al0300">Image 53</alt-text></inline-graphic></td><td align="char">&#x02212;5.40</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Gln110</td></tr><tr><td>15</td><td>Tideglusib</td><td><inline-graphic xlink:href="t54_lrg.gif"><alt-text id="al0305">Image 54</alt-text></inline-graphic></td><td align="char">&#x02212;5.95</td><td>2-Arene-h interaction with Asp289&#x00026;Tyr239, one Arene-cation bonding with Lys137.</td></tr><tr><td>16</td><td>Carmofur</td><td><inline-graphic xlink:href="t55_lrg.gif"><alt-text id="al0310">Image 55</alt-text></inline-graphic></td><td align="char">&#x02212;6.53</td><td>Arene-cation interaction with Arg298</td></tr><tr><td>17</td><td>Ebselen</td><td><inline-graphic xlink:href="t56_lrg.gif"><alt-text id="al0315">Image 56</alt-text></inline-graphic></td><td align="char">&#x02212;5.90</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction between Se and Ala7</td></tr><tr><td>18</td><td>Cinanserin</td><td><inline-graphic xlink:href="t57_lrg.gif"><alt-text id="al0320">Image 57</alt-text></inline-graphic></td><td align="char">&#x02212;6.72</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction and Arene-H bonding with Asn142 &#x00026;Gly143</td></tr><tr><td>19</td><td>Hydroxychloroquine</td><td><inline-graphic xlink:href="t58_lrg.gif"><alt-text id="al0325">Image 58</alt-text></inline-graphic></td><td align="char">&#x02212;5.86</td><td/></tr></tbody></table></table-wrap><table-wrap position="float" id="t0030"><label>Table 6</label><caption><p>Summary of interactions in case of natural sources optimized for <italic>Escherichia coli</italic> BL<sub>21</sub> (DE<sub>3</sub>).</p></caption><alt-text id="al0330">Table 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Cpd. name</th><th>Docking interaction</th><th>Docking score</th><th>Interpretation</th></tr></thead><tbody><tr><td>1</td><td>L-tyrosine zwitterion</td><td><inline-graphic xlink:href="t59_lrg.gif"><alt-text id="al0335">Image 59</alt-text></inline-graphic></td><td align="char">&#x02212;4.21</td><td>3-H-bonding with Thr199, Glu288, and Asp289</td></tr><tr><td>2</td><td>L-threonine zwitterion</td><td><inline-graphic xlink:href="t60_lrg.gif"><alt-text id="al0340">Image 60</alt-text></inline-graphic></td><td align="char">&#x02212;3.94</td><td>H-bonding with Lys88</td></tr><tr><td>3</td><td>L-leucine</td><td><inline-graphic xlink:href="t61_lrg.gif"><alt-text id="al0345">Image 61</alt-text></inline-graphic></td><td align="char">&#x02212;3.98</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> bonding with lys97, H-bonding with Met17</td></tr><tr><td>4</td><td>L-alanine zwitterion</td><td><inline-graphic xlink:href="t62_lrg.gif"><alt-text id="al0350">Image 62</alt-text></inline-graphic></td><td align="char">&#x02212;4.01</td><td>2-H-bonding with Ala7, Met6, and <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Arg298</td></tr><tr><td>5</td><td>(2<italic>R</italic>)-2-ammonio-4-(ethylsulfanyl)butanoate</td><td><inline-graphic xlink:href="t63_lrg.gif"><alt-text id="al0355">Image 63</alt-text></inline-graphic></td><td align="char">&#x02212;4.15</td><td>H-bonding with Glu288,290, Asp289, <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Lys137, Asp197</td></tr><tr><td>6</td><td>(2<italic>S</italic>,4<italic>R</italic>)-2-ammonio-4-carbamoylpentanedioate</td><td><inline-graphic xlink:href="t64_lrg.gif"><alt-text id="al0360">Image 64</alt-text></inline-graphic></td><td align="char">&#x02212;4.12</td><td>Anion-anion and <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interactions with Lys137, Arg131, 3-H-bonding with Glu288, 290, Asp289</td></tr><tr><td>7</td><td>(4-(((2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl)methyl)amino)benzoyl) glutamic acid</td><td><inline-graphic xlink:href="t65_lrg.gif"><alt-text id="al0365">Image 65</alt-text></inline-graphic></td><td align="char">&#x02212;7.17</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Gly71</td></tr><tr><td>8</td><td>(2<italic>S</italic>)-2-ammonio-3-(3-methylimidazol-4-yl) propanoate</td><td><inline-graphic xlink:href="t66_lrg.gif"><alt-text id="al0370">Image 66</alt-text></inline-graphic></td><td align="char">&#x02212;4.14</td><td>2-H-bonding with Thr199, Asp289</td></tr><tr><td>9</td><td>D-asparagine</td><td><inline-graphic xlink:href="t67_lrg.gif"><alt-text id="al0375">Image 67</alt-text></inline-graphic></td><td align="char">&#x02212;3.84</td><td>Anion-anion and <italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interactions with Lys137, Arg131, 3-H-bonding with Leu287, Asp289, Glu290</td></tr><tr><td>10</td><td>O-phosphonato-<sc>l</sc>-serine(2-)</td><td><inline-graphic xlink:href="t68_lrg.gif"><alt-text id="al0380">Image 68</alt-text></inline-graphic></td><td align="char">&#x02212;3.91</td><td>Anion-anion interaction with Lys88, 90</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0035"><label>Table 7</label><caption><p>Summary of interactions in case of natural inhibitory ligands against COVID-19 downloaded from PubChem.</p></caption><alt-text id="al0385">Table 7</alt-text><table frame="hsides" rules="groups"><thead><tr><th>#</th><th>Cpd. CID</th><th>Docking interaction</th><th>Docking score</th><th>Interpretation</th></tr></thead><tbody><tr><td>1</td><td align="char">753</td><td><inline-graphic xlink:href="t69_lrg.gif"><alt-text id="al0390">Image 69</alt-text></inline-graphic></td><td align="char">&#x02212;4.02</td><td>H-bonding with Met6</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>2</td><td align="char">787400</td><td><inline-graphic xlink:href="t70_lrg.gif"><alt-text id="al0395">Image 70</alt-text></inline-graphic></td><td align="char">&#x02212;5.20</td><td>H-bonding with Thr199</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>3</td><td align="char">24758425</td><td><inline-graphic xlink:href="t71_lrg.gif"><alt-text id="al0400">Image 71</alt-text></inline-graphic></td><td align="char">&#x02212;5.84</td><td/></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>4</td><td align="char">311</td><td><inline-graphic xlink:href="t72_lrg.gif"><alt-text id="al0405">Image 72</alt-text></inline-graphic></td><td align="char">&#x02212;4.30</td><td>2-H-bonding with Leu287, Asp197<break/><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interactions with Lys137, Asp289</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>5</td><td align="char">17754054</td><td><inline-graphic xlink:href="t73_lrg.gif"><alt-text id="al0410">Image 73</alt-text></inline-graphic></td><td align="char">&#x02212;4.86</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Gly71, 2-H-bonding with Met17, Lys97</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>6</td><td align="char">6083</td><td><inline-graphic xlink:href="t74_lrg.gif"><alt-text id="al0415">Image 74</alt-text></inline-graphic></td><td align="char">&#x02212;5.46</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Lys90, H-bonding with Gln83</td></tr><tr><td>7</td><td align="char">24139</td><td><inline-graphic xlink:href="t75_lrg.gif"><alt-text id="al0420">Image 75</alt-text></inline-graphic></td><td align="char">&#x02212;4.86</td><td><italic>&#x003c0;</italic>&#x02013;<italic>&#x003c0;</italic> interaction with Lys97, 2-H-bonding with Met17, Glu14</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>8</td><td align="char">24310</td><td><inline-graphic xlink:href="t76_lrg.gif"><alt-text id="al0425">Image 76</alt-text></inline-graphic></td><td align="char">&#x02212;4.96</td><td>4-H-bonding with Met6, Arg298</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>9</td><td align="char">439,680</td><td><inline-graphic xlink:href="t77_lrg.gif"><alt-text id="al0430">Image 77</alt-text></inline-graphic></td><td align="char">&#x02212;5.07</td><td>5-H-bonding with Gln299, Asp295, Met6</td></tr><tr><td/><td align="char"/><td/><td align="char"/><td/></tr><tr><td>10</td><td align="char">445794</td><td><inline-graphic xlink:href="t78_lrg.gif"><alt-text id="al0435">Image 78</alt-text></inline-graphic></td><td align="char">&#x02212;6.39</td><td>2-H-bonding with Leu287, Asp197</td></tr></tbody></table></table-wrap><fig id="f0010"><label>Fig. 2</label><caption><p>Ligands interaction with their surface maps.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p></sec><sec id="s0030"><label>4</label><title>Conclusion</title><p id="p0045">The newly emerged COVID-19 virus is a serious health concern in the 20th century. Although there is a sequence of medical drugs and natural products demonstrated high binding affinity to various viral proteins, the development of an in-vivo and in-vitro medical inhibitory drug for SARS-CoV-2 is a challenging and time-consuming task. As a result, in silico and bioinformatic routes is a fast way to assess an effective drug against SARS-CoV-2. A rigorous computational docking was pursued to identify the antiviral activity of any drug before medical usage. The present study screened the inhibitory effect of 39 ligands based on molecular docking of 6YB7 protease. The docking results exhibited that the reported ligands exhibit a high binding affinity to the COVID-19 protease and can inhibit its viral infection. Ritonavir antiviral drug binds to SARS-CoV-2 main protease with a score of &#x02212;8.12, so it is expected that ritonavir is a potent inhibitor for SARS-CoV-2 pneumonia. The results obtained in this study are based on computer docking simulation, and no in vivo and in vitro anti-viral assessment conducted till now, since the author aims to share these results with medical scientists to face SARS-CoV-2 epidemic urgently.</p></sec><sec id="s1000"><title>CRediT authorship contribution statement</title><p id="p3135">
<bold>A.N. El-hoshoudy:</bold> Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review &#x00026; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0050">The authors declare that they have no known competing for financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><source>Acta Pharm. Sin. B</source><volume>10</volume><issue>5</issue><year>2020</year><fpage>766</fpage><lpage>788</lpage></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.-J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><fpage>281</fpage><lpage>292.e6</lpage><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="book" id="rf0015"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><chapter-title>Mass Medical Soc</chapter-title><year>2020</year></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Lan</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><source>Cell Res.</source><year>2020</year><fpage>1</fpage><pub-id pub-id-type="pmid">31802008</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>I.M.</given-names></name><name><surname>Abdelmalek</surname><given-names>D.H.</given-names></name><name><surname>Elshahat</surname><given-names>M.E.</given-names></name><name><surname>Elfiky</surname><given-names>A.A.</given-names></name></person-group><source>J. Inf. Secur.</source><volume>80</volume><issue>5</issue><year>2020</year><fpage>554</fpage><lpage>562</lpage></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="book" id="rf0030"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>B.</given-names></name></person-group><chapter-title>Possible Importance of the KRSFIEDLLFNKV Motif, Circulated and Published on ResearchGate [Google Scholar]</chapter-title><year>2010</year></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>B.</given-names></name></person-group><source>Comput. Biol. Med.</source><year>2020</year><fpage>103670</fpage><pub-id pub-id-type="pmid">32209231</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Madani</surname><given-names>T.A.</given-names></name><name><surname>Ntoumi</surname><given-names>F.</given-names></name><name><surname>Kock</surname><given-names>R.</given-names></name><name><surname>Dar</surname><given-names>O.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Mchugh</surname><given-names>T.D.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name></person-group><source>Int. J. Infect. Dis.</source><volume>91</volume><year>2020</year><fpage>264</fpage><pub-id pub-id-type="pmid">31953166</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Sahraei</surname><given-names>Z.</given-names></name><name><surname>Shabani</surname><given-names>M.</given-names></name><name><surname>Shokouhi</surname><given-names>S.</given-names></name><name><surname>Saffaei</surname><given-names>A.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><year>2020</year><object-id pub-id-type="publisher-id">105945</object-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Peng</surname><given-names>C.</given-names></name></person-group><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Tobaiqy</surname><given-names>M.</given-names></name><name><surname>Qashqary</surname><given-names>M.</given-names></name><name><surname>Al-Dahery</surname><given-names>S.</given-names></name><name><surname>Mujallad</surname><given-names>A.</given-names></name><name><surname>Hershan</surname><given-names>A.A.</given-names></name><name><surname>Kamal</surname><given-names>M.A.</given-names></name><name><surname>Helmi</surname><given-names>N.</given-names></name></person-group><source>Infection Prevention in Practice</source><year>2020</year><fpage>100061</fpage></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Parola</surname><given-names>P.</given-names></name><name><surname>Meddeb</surname><given-names>L.</given-names></name><name><surname>Mailhe</surname><given-names>M.</given-names></name><name><surname>Doudier</surname><given-names>B.</given-names></name><name><surname>Courjon</surname><given-names>J.</given-names></name><name><surname>Giordanengo</surname><given-names>V.</given-names></name><name><surname>Vieira</surname><given-names>V.E.</given-names></name><name><surname>Dupont</surname><given-names>H.T.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><volume>56</volume><issue>1</issue><year>2020</year><object-id pub-id-type="publisher-id">105949</object-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.-C.</given-names></name><name><surname>Shih</surname><given-names>T.-P.</given-names></name><name><surname>Ko</surname><given-names>W.-C.</given-names></name><name><surname>Tang</surname><given-names>H.-J.</given-names></name><name><surname>Hsueh</surname><given-names>P.-R.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><year>2020</year><fpage>105924</fpage><pub-id pub-id-type="pmid">32081636</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name></person-group><source>Life Sci.</source><year>2020</year><fpage>117592</fpage><pub-id pub-id-type="pmid">32222463</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Bogoch</surname><given-names>I.I.</given-names></name><name><surname>Watts</surname><given-names>A.</given-names></name><name><surname>Thomas-Bachli</surname><given-names>A.</given-names></name><name><surname>Huber</surname><given-names>C.</given-names></name><name><surname>Kraemer</surname><given-names>M.U.</given-names></name><name><surname>Khan</surname><given-names>K.</given-names></name></person-group><source>J. Travel Med.</source><volume>27</volume><issue>2</issue><year>2020</year><fpage>1</fpage><lpage>3</lpage></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Rothan</surname><given-names>H.A.</given-names></name><name><surname>Byrareddy</surname><given-names>S.N.</given-names></name></person-group><source>J. Autoimmun.</source><year>2020</year><fpage>102433</fpage><pub-id pub-id-type="pmid">32113704</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name></person-group><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name></person-group><source>New Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.-M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.-G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>Z.-W.</given-names></name><name><surname>Tian</surname><given-names>J.-H.</given-names></name><name><surname>Pei</surname><given-names>Y.-Y.</given-names></name></person-group><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Landt</surname><given-names>O.</given-names></name><name><surname>Kaiser</surname><given-names>M.</given-names></name><name><surname>Molenkamp</surname><given-names>R.</given-names></name><name><surname>Meijer</surname><given-names>A.</given-names></name><name><surname>Chu</surname><given-names>D.K.</given-names></name><name><surname>Bleicker</surname><given-names>T.</given-names></name><name><surname>Br&#x000fc;nink</surname><given-names>S.</given-names></name><name><surname>Schneider</surname><given-names>J.</given-names></name><name><surname>Schmidt</surname><given-names>M.L.</given-names></name></person-group><source>Eurosurveillance</source><volume>25</volume><year>2020</year><object-id pub-id-type="publisher-id">2000045</object-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.-s.</given-names></name><name><surname>Wang</surname><given-names>Y.-r.</given-names></name><name><surname>Ye</surname><given-names>D.-w.</given-names></name><name><surname>Liu</surname><given-names>Q.-q.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><year>2020</year><fpage>105948</fpage><pub-id pub-id-type="pmid">32201353</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>J.-W.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>G.-Q.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><year>2020</year><fpage>105954</fpage><pub-id pub-id-type="pmid">32234467</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>X.</given-names></name></person-group><source>npj Vaccines</source><volume>5</volume><year>2020</year><fpage>1</fpage><pub-id pub-id-type="pmid">31908850</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Pillaiyar</surname><given-names>T.</given-names></name><name><surname>Manickam</surname><given-names>M.</given-names></name><name><surname>Namasivayam</surname><given-names>V.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Jung</surname><given-names>S.-H.</given-names></name></person-group><source>J. Med. Chem.</source><volume>59</volume><year>2016</year><fpage>6595</fpage><pub-id pub-id-type="pmid">26878082</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name><name><surname>Mahdy</surname><given-names>S.M.</given-names></name><name><surname>Elshemey</surname><given-names>W.M.</given-names></name></person-group><source>J. Med. Virol.</source><volume>89</volume><year>2017</year><fpage>1040</fpage><pub-id pub-id-type="pmid">27864902</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Lang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Koerhuis</surname><given-names>D.</given-names></name><name><surname>Boons</surname><given-names>G.-J.</given-names></name><name><surname>Bosch</surname><given-names>B.-J.</given-names></name><name><surname>Rey</surname><given-names>F.A.</given-names></name><name><surname>de Groot</surname><given-names>R.J.</given-names></name></person-group><source>Nat. Struct. Mol. Biol.</source><volume>26</volume><year>2019</year><fpage>481</fpage><pub-id pub-id-type="pmid">31160783</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Millet</surname><given-names>J.K.</given-names></name><name><surname>Licitra</surname><given-names>B.N.</given-names></name><name><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><source>Viruses</source><volume>4</volume><year>2012</year><fpage>1011</fpage><pub-id pub-id-type="pmid">22816037</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><source>Annual Review of Virology</source><volume>3</volume><year>2016</year><fpage>237</fpage></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Kirchdoerfer</surname><given-names>R.N.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Pallesen</surname><given-names>J.</given-names></name><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Turner</surname><given-names>H.L.</given-names></name><name><surname>Cottrell</surname><given-names>C.A.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Ward</surname><given-names>A.B.</given-names></name></person-group><source>Sci. Rep.</source><volume>8</volume><year>2018</year><fpage>1</fpage><pub-id pub-id-type="pmid">29311619</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Gui</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name></person-group><source>PLoS Path.</source><volume>14</volume><year>2018</year><object-id pub-id-type="publisher-id">e1007236</object-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>J.</given-names></name><name><surname>Di Scala</surname><given-names>C.</given-names></name><name><surname>Chahinian</surname><given-names>H.</given-names></name><name><surname>Yahi</surname><given-names>N.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><volume>55</volume><issue>5</issue><year>2020</year><object-id pub-id-type="publisher-id">105960</object-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>FB</surname><given-names>A.B.</given-names></name><name><surname>Sarialioglu</surname><given-names>F.</given-names></name></person-group><source>Med. Hypotheses</source><volume>142</volume><year>2020</year><object-id pub-id-type="publisher-id">109743</object-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>J.K.</given-names></name><name><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><source>Virus Res.</source><volume>202</volume><year>2015</year><fpage>120</fpage><pub-id pub-id-type="pmid">25445340</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Park</surname><given-names>Y.-J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Snijder</surname><given-names>J.</given-names></name><name><surname>Quispe</surname><given-names>J.</given-names></name><name><surname>Cameroni</surname><given-names>E.</given-names></name><name><surname>Gopal</surname><given-names>R.</given-names></name><name><surname>Dai</surname><given-names>M.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><source>Cell</source><volume>176</volume><year>2019</year><fpage>1026</fpage><pub-id pub-id-type="pmid">30712865</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Snijder</surname><given-names>J.</given-names></name><name><surname>Yoshioka</surname><given-names>C.</given-names></name><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Rey</surname><given-names>F.A.</given-names></name><name><surname>Bosch</surname><given-names>B.-J.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><source>J. Virol.</source><volume>92</volume><year>2018</year><object-id pub-id-type="publisher-id">e01628</object-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>A.</given-names></name><name><surname>Le</surname><given-names>N.T.T.</given-names></name><name><surname>Selisko</surname><given-names>B.</given-names></name><name><surname>Eydoux</surname><given-names>C.</given-names></name><name><surname>Alvarez</surname><given-names>K.</given-names></name><name><surname>Guillemot</surname><given-names>J.-C.</given-names></name><name><surname>Decroly</surname><given-names>E.</given-names></name><name><surname>Peersen</surname><given-names>O.</given-names></name><name><surname>Ferron</surname><given-names>F.</given-names></name><name><surname>Canard</surname><given-names>B.</given-names></name></person-group><source>Antivir. Res.</source><year>2020</year><fpage>104793</fpage><pub-id pub-id-type="pmid">32283108</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><mixed-citation publication-type="other" id="or0005">S. Kumar, 2020 (2020).</mixed-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="book" id="rf0190"><person-group person-group-type="author"><name><surname>Nishiura</surname><given-names>H.</given-names></name><name><surname>Jung</surname><given-names>S.-m.</given-names></name><name><surname>Linton</surname><given-names>N.M.</given-names></name><name><surname>Kinoshita</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Yuan</surname><given-names>B.</given-names></name><name><surname>Akhmetzhanov</surname><given-names>A.R.</given-names></name></person-group><chapter-title>Multidisciplinary Digital Publishing Institute</chapter-title><year>2020</year></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Macchiagodena</surname><given-names>M.</given-names></name><name><surname>Pagliai</surname><given-names>M.</given-names></name><name><surname>Procacci</surname><given-names>P.</given-names></name></person-group><source>Chem. Phys. Lett.</source><year>2020</year><fpage>137489</fpage><pub-id pub-id-type="pmid">32313296</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B.W.</given-names></name><name><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><source>Adv. Drug Del. Rev.</source><volume>23</volume><year>1997</year><fpage>3</fpage></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Perricone</surname><given-names>C.</given-names></name><name><surname>Triggianese</surname><given-names>P.</given-names></name><name><surname>Bartoloni</surname><given-names>E.</given-names></name><name><surname>Cafaro</surname><given-names>G.</given-names></name><name><surname>Bonifacio</surname><given-names>A.F.</given-names></name><name><surname>Bursi</surname><given-names>R.</given-names></name><name><surname>Perricone</surname><given-names>R.</given-names></name><name><surname>Gerli</surname><given-names>R.</given-names></name></person-group><source>J. Autoimmun.</source><year>2020</year><fpage>102468</fpage><pub-id pub-id-type="pmid">32317220</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><source>BMC Res. Notes</source><volume>8</volume><year>2015</year><fpage>9</fpage><pub-id pub-id-type="pmid">25595103</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Chitrala</surname><given-names>K.N.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Busbee</surname><given-names>B.</given-names></name><name><surname>Singh</surname><given-names>N.P.</given-names></name><name><surname>Bonati</surname><given-names>L.</given-names></name><name><surname>Xing</surname><given-names>Y.</given-names></name><name><surname>Nagarkatti</surname><given-names>P.</given-names></name><name><surname>Nagarkatti</surname><given-names>M.</given-names></name></person-group><source>Sci. Rep.</source><volume>9</volume><issue>1</issue><year>2019</year></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Colson</surname><given-names>P.</given-names></name><name><surname>Rolain</surname><given-names>J.-M.</given-names></name><name><surname>Lagier</surname><given-names>J.-C.</given-names></name><name><surname>Brouqui</surname><given-names>P.</given-names></name><name><surname>Raoult</surname><given-names>D.</given-names></name></person-group><source>Int. J. Antimicrob. Agents</source><year>2020</year><object-id pub-id-type="publisher-id">105932</object-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>269</fpage><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H.X.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>K.Q.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Bai</surname><given-names>D.L.</given-names></name><name><surname>Chen</surname><given-names>K.X.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>H.L.</given-names></name></person-group><source>Acta Pharmacol. Sin.</source><volume>26</volume><year>2005</year><fpage>1201</fpage><pub-id pub-id-type="pmid">16174436</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Ahmed-Belkacem</surname><given-names>A.</given-names></name><name><surname>Colliandre</surname><given-names>L.</given-names></name><name><surname>Ahnou</surname><given-names>N.</given-names></name><name><surname>Nevers</surname><given-names>Q.</given-names></name><name><surname>Gelin</surname><given-names>M.</given-names></name><name><surname>Bessin</surname><given-names>Y.</given-names></name><name><surname>Brillet</surname><given-names>R.</given-names></name><name><surname>Cala</surname><given-names>O.</given-names></name><name><surname>Douguet</surname><given-names>D.</given-names></name><name><surname>Bourguet</surname><given-names>W.</given-names></name></person-group><source>Nat. Commun.</source><volume>7</volume><issue>1</issue><year>2016</year></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>S.</given-names></name><name><surname>Gallay</surname><given-names>P.A.</given-names></name></person-group><source>Biochimica et Biophysica Acta (BBA)-General Subjects</source><volume>1850</volume><year>2015</year><fpage>2103</fpage><pub-id pub-id-type="pmid">25445708</pub-id></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Batool</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Patra</surname><given-names>M.C.</given-names></name><name><surname>Yesudhas</surname><given-names>D.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name></person-group><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>1</fpage><pub-id pub-id-type="pmid">28127051</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Elfiky</surname><given-names>A.A.</given-names></name><name><surname>Ismail</surname><given-names>A.</given-names></name></person-group><source>Life Sci.</source><volume>238</volume><year>2019</year><fpage>116958</fpage><pub-id pub-id-type="pmid">31628915</pub-id></element-citation></ref></ref-list><sec id="s0035" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0055">
<supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary tables</p></caption><media xlink:href="mmc1.docx"><alt-text>Image 79</alt-text></media></supplementary-material>
</p></sec><fn-group><fn id="s0040" fn-type="supplementary-material"><label>Appendix A</label><p id="p0060">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molliq.2020.113968" id="ir0045">https://doi.org/10.1016/j.molliq.2020.113968</ext-link>.</p></fn></fn-group></back></article>